最新观点
Insights From Our Experts
Articles
Left-Right-Left: The Latest in Pharma-Payer Ping Pong
Biopharmaceutical companies have offered financial assistance for commercially covered patients’ out-of-pocket (OOP) cost sharing for 20+ years. However, in the ongoing evolution of controlling versus encouraging patient access to specific drugs, payers and biopharma also have…
Your Guide to Developing a Best-in-Class Specialty Pharmacy Network Strategy
Why Develop a Specialty Pharmacy Network Strategy? Specialty pharmaceuticals often require high-touch, labor-intensive services to expedite patient access and improve therapy adherence. Additionally, patients requiring specialty therapies are often medically complex and challenging to manage. These…
Value Proposition of Medical Information Services: Current Perspectives from the Industry
Medical Information (MI) is an important customer facing function of pharmaceutical companies that plays a crucial role in addressing inquiries from healthcare professionals, payors, and patients and caregivers and ensuring pharmaceutical products’ safe and effective use.…
Employ an Integrated Market Access Strategy to Deliver Brand Success
The pharma/life sciences pipeline is vibrant, with ongoing innovation bringing new hope to patients and providers across many therapeutic areas. Against the backdrop of rapid scientific advancement in and precision medicine and targeted therapies in primary…
Solving the Wastage Challenge Through Predictive Analytics and Modeling
“Solving the Wastage Challenge Through Predictive Analytics and Modeling,” authored by John Chatas, Principal, Specialty Consulting, EVERSANA and Lee Ann Steadman, Senior Vice President, Specialty Consulting, EVERSANA explores how legislative changes like the Wastage Reduction Act…
What EVERSANA’s Growing Abstract Count at ISPOR U.S. Means to the HEOR Industry
EVERSANA’s Value & Evidence (V&E) and Data & Analytics (D&A) team collectively had an impressive 27 abstracts accepted to ISPOR U.S. 2023, showcasing EVERSANA’s ability to cross-solve for clients’ HEOR needs. EVERSANA’s Value & Evidence and…
Peeking Behind the PBM-lead GPO Curtain
‘PBM-lead GPO,’ a Newly Created Term to Describe Large Scale PBM-Owned Rebate Aggregators PBM-led group purchasing organizations (GPOs) are not true group purchasing organizations in scope, nor are they pure rebate aggregators. Rather, PBM-lead GPOs are…
When Will “Digital Health” Just Become Health?
Despite the significant drop in funding in 2022, digital health is here to stay. It encompasses a wide range of technologies and innovations, from telemedicine to wearables to artificial intelligence (AI). Telehealth has reached 80% adoption…
Elevating Field Reimbursement Manager Performance through Insights & Comparative Data
“Elevating Field Reimbursement Managers’ Performance through Customer-based Insights and Comparative Data,” authored by David Frey, Principal, Specialty Consulting, EVERSANA and Lee Ann Steadman, Senior Vice President, Specialty Consulting, EVERSANA explores the evolving role of Field Reimbursement…
Breaking Down Q1 2023 Digital Health Policy Updates
Insights and Implications on AI/ML Software, Companion Apps for Pharma, Digital Diagnostics, VR Software, Breakthrough Devices, and More There was a barrage of activity by FDA in Digital Health at the end of 2022, including the…